DK3412305T3 - Behandling af koagulationssygdom ved administration af rekombinant vwf - Google Patents

Behandling af koagulationssygdom ved administration af rekombinant vwf Download PDF

Info

Publication number
DK3412305T3
DK3412305T3 DK18173179.5T DK18173179T DK3412305T3 DK 3412305 T3 DK3412305 T3 DK 3412305T3 DK 18173179 T DK18173179 T DK 18173179T DK 3412305 T3 DK3412305 T3 DK 3412305T3
Authority
DK
Denmark
Prior art keywords
administration
treatment
recombinant vwf
coagulation disease
coagulation
Prior art date
Application number
DK18173179.5T
Other languages
Danish (da)
English (en)
Inventor
Friedrich Scheiflinger
Peter Dr Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of DK3412305T3 publication Critical patent/DK3412305T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK18173179.5T 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf DK3412305T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15
EP12728919.7A EP2717905B1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Publications (1)

Publication Number Publication Date
DK3412305T3 true DK3412305T3 (da) 2021-03-01

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18173179.5T DK3412305T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf
DK20216368.9T DK3858375T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf
DK12728919.7T DK2717905T3 (en) 2011-06-10 2012-06-11 TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK20216368.9T DK3858375T3 (da) 2011-06-10 2012-06-11 Behandling af koagulationssygdom ved administration af rekombinant vwf
DK12728919.7T DK2717905T3 (en) 2011-06-10 2012-06-11 TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF

Country Status (24)

Country Link
US (2) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2680402C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2020009788A (es) * 2018-03-21 2020-12-09 Takeda Pharmaceuticals Co Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.
KR20210134642A (ko) * 2019-02-01 2021-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf (rvwf)를 이용한 예방 치료 방법
US20220401524A1 (en) * 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
IL303089A (en) * 2020-11-24 2023-07-01 Band Therapeutics Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
BRPI0820271A2 (pt) 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
TWI670072B (zh) * 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組vwf調配物
JP2013500743A (ja) * 2009-08-04 2013-01-10 バクスター・インターナショナル・インコーポレイテッド Fviiiおよびvwfがノックアウトされた遺伝子導入マウス−血友病aモデル
ES3037386T3 (en) 2010-07-08 2025-10-01 Takeda Pharmaceuticals Co Method of producing recombinant high molecular weight vwf in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病

Also Published As

Publication number Publication date
EP3858375A1 (en) 2021-08-04
HRP20180962T1 (hr) 2018-10-19
RU2014100107A (ru) 2015-07-20
DK3858375T3 (da) 2024-04-15
JP2017019788A (ja) 2017-01-26
KR20200091476A (ko) 2020-07-30
ES2976169T3 (es) 2024-07-24
EP3858375B1 (en) 2024-03-20
PL3412305T3 (pl) 2021-05-31
LT2717905T (lt) 2018-10-10
CA2838845C (en) 2019-08-06
PT3412305T (pt) 2021-01-29
RU2017102679A3 (enExample) 2018-12-19
RU2017102679A (ru) 2018-12-19
FI3858375T3 (fi) 2024-04-17
TR201808823T4 (tr) 2018-07-23
SI2717905T1 (sl) 2018-09-28
EP3412305A1 (en) 2018-12-12
HK1257436A1 (zh) 2019-10-18
NZ618790A (en) 2015-07-31
RU2019103386A (ru) 2020-08-07
KR20140039285A (ko) 2014-04-01
HUE039317T2 (hu) 2018-12-28
ES2682249T3 (es) 2018-09-19
AU2012267458A1 (en) 2014-01-09
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
MX2013014543A (es) 2014-06-11
KR20190041032A (ko) 2019-04-19
EP3412305B1 (en) 2021-01-06
AU2022201518B2 (en) 2025-07-03
AU2017206235B2 (en) 2019-10-17
AU2016202299B2 (en) 2017-07-20
SG10202002591QA (en) 2020-05-28
MX350582B (es) 2017-09-11
US20160184403A1 (en) 2016-06-30
US20120316116A1 (en) 2012-12-13
RU2680402C2 (ru) 2019-02-21
JP6347468B2 (ja) 2018-06-27
CN107412743B (zh) 2021-07-02
ES2860450T3 (es) 2021-10-05
CN108210889A (zh) 2018-06-29
KR102319868B1 (ko) 2021-11-01
MX2020000083A (es) 2020-08-06
PT3858375T (pt) 2024-04-18
JP2019048892A (ja) 2019-03-28
EP2717905A1 (en) 2014-04-16
CN107412743A (zh) 2017-12-01
JP6527114B2 (ja) 2019-06-05
AU2020200026A1 (en) 2020-01-30
PT2717905T (pt) 2018-07-02
JP2014516088A (ja) 2014-07-07
RU2628537C2 (ru) 2017-08-18
US9272021B2 (en) 2016-03-01
AU2017206235A1 (en) 2017-08-03
RU2019103386A3 (enExample) 2022-01-24
CN103732244A (zh) 2014-04-16
AU2022201518A1 (en) 2022-03-24
BR112013031795A2 (pt) 2016-12-20
AU2016202299A1 (en) 2016-05-05
SG10201604684WA (en) 2016-07-28
AR086904A1 (es) 2014-01-29
WO2012171031A1 (en) 2012-12-13
PL2717905T3 (pl) 2018-10-31
CA2838845A1 (en) 2012-12-13
DK2717905T3 (en) 2018-07-02
EP2717905B1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
DK3858375T3 (da) Behandling af koagulationssygdom ved administration af rekombinant vwf
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CO6930321A2 (es) Curación de tejidos
DK2931891T3 (da) Rna-styret modificering af menneskelige genomer
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
DK2717941T3 (da) Behandling af cancer
DK2844279T3 (da) Doseringsprogrammer til behandling af pompes sygdom
DK2785349T4 (da) Kombinationsbehandling af cancer
DK3011936T3 (da) Vævsmanipulerede konstrukter
DK2701697T3 (da) Oxidative nethindesygdomme
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
DK2773379T3 (da) Subkutan indgivelse af polymerkonjugater af terapeutiske midler
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK3603704T3 (da) Indgivelse af medikament
EP2734841A4 (en) PHOTONIC BLOOD GROUP DETERMINATION
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
IL231121A0 (en) Treatment of degenerative joint disease
LT2768859T (lt) Il17c antagonistai, skirti uždegiminių ligų gydymui
DK2673363T3 (da) Behandling af angiogenesesygdomme
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
EP2750709A4 (en) TREATMENT OF KACHEXIE
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
PT2493147E (pt) Agulha flash de sangue